Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Non-alcoholic Fatty Liver Disease | 8 | 2024 | 173 | 3.360 |
Why?
|
| Sexual and Gender Minorities | 7 | 2023 | 205 | 2.670 |
Why?
|
| Liver Transplantation | 11 | 2024 | 1177 | 2.380 |
Why?
|
| Hepatitis B | 3 | 2022 | 75 | 1.880 |
Why?
|
| Gastroenterology | 7 | 2024 | 144 | 1.650 |
Why?
|
| Transgender Persons | 4 | 2024 | 105 | 1.380 |
Why?
|
| Hepatitis B, Chronic | 3 | 2017 | 32 | 1.240 |
Why?
|
| Virus Activation | 3 | 2017 | 41 | 1.230 |
Why?
|
| End Stage Liver Disease | 6 | 2024 | 60 | 1.180 |
Why?
|
| Hepatitis B virus | 4 | 2022 | 43 | 1.010 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 413 | 0.980 |
Why?
|
| Antiviral Agents | 6 | 2022 | 475 | 0.970 |
Why?
|
| Hepatitis C, Chronic | 3 | 2019 | 91 | 0.950 |
Why?
|
| Women's Rights | 1 | 2024 | 7 | 0.930 |
Why?
|
| Hepatitis A | 1 | 2022 | 3 | 0.830 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2022 | 23 | 0.820 |
Why?
|
| Kidney Transplantation | 2 | 2019 | 849 | 0.820 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 4 | 2023 | 43 | 0.810 |
Why?
|
| Donor Selection | 2 | 2019 | 74 | 0.780 |
Why?
|
| Abortion, Induced | 1 | 2024 | 131 | 0.750 |
Why?
|
| Transplant Recipients | 2 | 2019 | 137 | 0.730 |
Why?
|
| Nephrology | 1 | 2019 | 41 | 0.650 |
Why?
|
| Healthcare Disparities | 3 | 2023 | 410 | 0.630 |
Why?
|
| Humans | 41 | 2024 | 89073 | 0.590 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2017 | 23 | 0.590 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 15 | 0.590 |
Why?
|
| Attitude to Health | 1 | 2018 | 222 | 0.580 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2021 | 575 | 0.570 |
Why?
|
| Hepatitis C | 1 | 2018 | 170 | 0.560 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2019 | 390 | 0.550 |
Why?
|
| Guanine | 1 | 2017 | 207 | 0.550 |
Why?
|
| Practice Guidelines as Topic | 2 | 2024 | 1043 | 0.540 |
Why?
|
| Tissue and Organ Procurement | 2 | 2019 | 345 | 0.520 |
Why?
|
| Gastroenterologists | 1 | 2016 | 31 | 0.520 |
Why?
|
| Graft Rejection | 3 | 2019 | 1067 | 0.490 |
Why?
|
| Hepatitis | 1 | 2014 | 34 | 0.480 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 29 | 0.480 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 754 | 0.470 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 643 | 0.470 |
Why?
|
| Guideline Adherence | 1 | 2016 | 229 | 0.470 |
Why?
|
| Liver Function Tests | 1 | 2014 | 92 | 0.460 |
Why?
|
| Uvula | 1 | 2013 | 6 | 0.450 |
Why?
|
| Gastroscopy | 1 | 2013 | 25 | 0.450 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 342 | 0.450 |
Why?
|
| Transsexualism | 2 | 2024 | 34 | 0.440 |
Why?
|
| Neoplasms | 3 | 2018 | 3035 | 0.430 |
Why?
|
| Fatty Liver | 1 | 2014 | 95 | 0.430 |
Why?
|
| Liver Diseases | 3 | 2023 | 242 | 0.400 |
Why?
|
| Deglutition Disorders | 1 | 2013 | 119 | 0.400 |
Why?
|
| Female | 19 | 2024 | 46014 | 0.400 |
Why?
|
| Pregnancy Complications | 1 | 2014 | 345 | 0.370 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 975 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 599 | 0.360 |
Why?
|
| Liver Cirrhosis | 5 | 2023 | 254 | 0.360 |
Why?
|
| Gender Identity | 3 | 2024 | 53 | 0.330 |
Why?
|
| United States | 8 | 2024 | 6957 | 0.320 |
Why?
|
| Adult | 15 | 2023 | 26508 | 0.320 |
Why?
|
| Waiting Lists | 2 | 2019 | 183 | 0.300 |
Why?
|
| Male | 13 | 2024 | 42254 | 0.280 |
Why?
|
| Gastrointestinal Tract | 3 | 2023 | 191 | 0.280 |
Why?
|
| Risk Factors | 5 | 2022 | 5466 | 0.280 |
Why?
|
| Mass Screening | 3 | 2018 | 636 | 0.270 |
Why?
|
| Sexual Behavior | 3 | 2023 | 309 | 0.270 |
Why?
|
| Tissue Donors | 2 | 2019 | 490 | 0.260 |
Why?
|
| Liver | 3 | 2019 | 1205 | 0.260 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 2612 | 0.250 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 738 | 0.240 |
Why?
|
| Gender Dysphoria | 1 | 2024 | 9 | 0.240 |
Why?
|
| Hepacivirus | 3 | 2019 | 129 | 0.230 |
Why?
|
| Digestive System Diseases | 1 | 2023 | 18 | 0.220 |
Why?
|
| Lactulose | 1 | 2023 | 22 | 0.220 |
Why?
|
| Hepatic Encephalopathy | 1 | 2023 | 39 | 0.220 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 82 | 0.220 |
Why?
|
| Age Factors | 2 | 2018 | 1867 | 0.210 |
Why?
|
| Pregnancy | 2 | 2024 | 3010 | 0.210 |
Why?
|
| Stomach | 1 | 2023 | 111 | 0.210 |
Why?
|
| Middle Aged | 9 | 2021 | 25865 | 0.200 |
Why?
|
| Quality of Life | 2 | 2021 | 1662 | 0.200 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2021 | 34 | 0.200 |
Why?
|
| Culturally Competent Care | 1 | 2021 | 12 | 0.190 |
Why?
|
| Ascites | 1 | 2021 | 56 | 0.190 |
Why?
|
| Allografts | 2 | 2019 | 181 | 0.190 |
Why?
|
| Retrospective Studies | 9 | 2023 | 9003 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 63 | 0.190 |
Why?
|
| Aged | 7 | 2021 | 19078 | 0.190 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2020 | 16 | 0.180 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2020 | 19 | 0.180 |
Why?
|
| Treatment Outcome | 7 | 2023 | 8203 | 0.180 |
Why?
|
| Graft Survival | 5 | 2022 | 898 | 0.170 |
Why?
|
| Racism | 1 | 2021 | 89 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2023 | 1837 | 0.170 |
Why?
|
| Cohort Effect | 1 | 2019 | 5 | 0.170 |
Why?
|
| Viremia | 1 | 2019 | 49 | 0.160 |
Why?
|
| Canada | 1 | 2019 | 208 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2021 | 237 | 0.160 |
Why?
|
| Fear | 1 | 2018 | 79 | 0.160 |
Why?
|
| Kidney Diseases | 1 | 2021 | 319 | 0.150 |
Why?
|
| Nursing Diagnosis | 1 | 2017 | 1 | 0.150 |
Why?
|
| Registries | 2 | 2019 | 778 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 414 | 0.150 |
Why?
|
| Internal Medicine | 1 | 2021 | 355 | 0.150 |
Why?
|
| Dyslipidemias | 1 | 2018 | 107 | 0.150 |
Why?
|
| Urban Population | 1 | 2018 | 224 | 0.150 |
Why?
|
| Weight Loss | 1 | 2018 | 225 | 0.140 |
Why?
|
| Prevalence | 1 | 2021 | 1240 | 0.140 |
Why?
|
| Hypertension | 1 | 2023 | 741 | 0.140 |
Why?
|
| Curriculum | 1 | 2021 | 567 | 0.140 |
Why?
|
| Rheumatologists | 1 | 2016 | 6 | 0.140 |
Why?
|
| Incidence | 2 | 2019 | 1592 | 0.140 |
Why?
|
| Dermatologists | 1 | 2016 | 2 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 418 | 0.130 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 26 | 0.130 |
Why?
|
| Oncologists | 1 | 2016 | 36 | 0.130 |
Why?
|
| Rituximab | 1 | 2016 | 119 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 1063 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 377 | 0.120 |
Why?
|
| Cholagogues and Choleretics | 1 | 2014 | 10 | 0.120 |
Why?
|
| Folic Acid Antagonists | 1 | 2014 | 19 | 0.120 |
Why?
|
| Colchicine | 1 | 2014 | 24 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2019 | 531 | 0.120 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2014 | 25 | 0.120 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 24 | 0.120 |
Why?
|
| Chicago | 1 | 2018 | 1423 | 0.120 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2014 | 70 | 0.120 |
Why?
|
| Kidney | 1 | 2019 | 1145 | 0.120 |
Why?
|
| Frozen Sections | 1 | 2014 | 49 | 0.110 |
Why?
|
| Methotrexate | 1 | 2014 | 250 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 415 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 988 | 0.110 |
Why?
|
| Risk Assessment | 2 | 2019 | 2291 | 0.110 |
Why?
|
| Heart Failure | 1 | 2023 | 1180 | 0.110 |
Why?
|
| Necrosis | 1 | 2013 | 209 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 2863 | 0.110 |
Why?
|
| Psoriasis | 1 | 2016 | 245 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 4273 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 699 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2021 | 1041 | 0.100 |
Why?
|
| Biopsy | 1 | 2014 | 1182 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 1591 | 0.080 |
Why?
|
| Prognosis | 1 | 2017 | 3773 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1715 | 0.080 |
Why?
|
| Patient Selection | 2 | 2021 | 682 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 2552 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2019 | 859 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 2412 | 0.060 |
Why?
|
| Digestion | 1 | 2023 | 8 | 0.060 |
Why?
|
| Atrial Pressure | 1 | 2023 | 6 | 0.050 |
Why?
|
| Platelet Count | 1 | 2023 | 93 | 0.050 |
Why?
|
| Minority Health | 1 | 2021 | 10 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2021 | 95 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 390 | 0.040 |
Why?
|
| Career Choice | 1 | 2021 | 148 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 231 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2024 | 435 | 0.040 |
Why?
|
| Stents | 1 | 2021 | 395 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 359 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 786 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2021 | 461 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2019 | 170 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 570 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 848 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2023 | 3717 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 780 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 1889 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3657 | 0.030 |
Why?
|
| Mice | 1 | 2023 | 11742 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 6289 | 0.020 |
Why?
|
| Animals | 1 | 2023 | 27324 | 0.010 |
Why?
|